U.S. patent number 3,689,504 [Application Number 05/101,441] was granted by the patent office on 1972-09-05 for n-substituted -alpha-methyl-3,4-(methylenedioxy) phenethylamines.
This patent grant is currently assigned to Abbott Laboratories, North Chicago, IL. Invention is credited to Bruce Wayne Horrom.
United States Patent |
3,689,504 |
|
September 5, 1972 |
N-SUBSTITUTED -ALPHA-METHYL-3,4-(METHYLENEDIOXY)
PHENETHYLAMINES
Abstract
N-substituted-.alpha.-methyl-3,4-(methylenedioxy)phenethylamines
of the formula: ##SPC1## Wherein R is cyclopropyl or
cyclopropylmethyl. The compounds are useful as appetite
depressants. 3 Claims, No Drawings
Inventors: |
Bruce Wayne Horrom (Waukegan,
IL) |
Assignee: |
Abbott Laboratories, North Chicago,
IL (N/A)
|
Family
ID: |
22284655 |
Appl.
No.: |
05/101,441 |
Filed: |
December 24, 1970 |
Current U.S.
Class: |
549/440; 549/442;
560/27; 564/219; 564/248; 564/374; 564/378; 564/381; 564/382 |
Current CPC
Class: |
C07D
317/58 (20130101) |
Current International
Class: |
C07D
317/58 (20060101); C07D 317/00 (20060101); C07d
013/10 () |
Field of
Search: |
;260/340.5 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
Horrom "Chemical Abstracts, "Vol. 71, 1969, Col. 12786g.
|
Primary Examiner: Alex Mazel
Assistant Examiner: James H. Turnipseed
Attorney, Agent or Firm: Robert L. Niblack
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of U.S. Ser. No.
770,126, filed Oct. 23, 1968 now abandoned.
Claims
1. A compound of the formula wherein R is cyclopropyl or
cyclopropylmethyl, or a pharmaceutically
2. A compound in accordance with claim 1 wherein R is
cyclopropyl,
3. A compound in accordance with claim 1 wherein R is
cyclopropylmethyl,
N-cyclopropylmethyl-.alpha.-methyl-3,4-(methylenedioxy)phenethylamine.
Description
DISCLOSURE
The problems caused by obesity are now well recognized and are
quite generally considered to be of sufficient importance that some
effort should be made to remedy the condition. Ordinarily, obesity
is caused simply by the caloric input to the body exceeding the
caloric output; adjustment may be achieved by reducing the input or
increasing the output. However, for many individuals such as the
aged or those suffering from infirmities, an increase in caloric
output is impossible or at least inadvisable. Therefore, some way
must be found to reduce the caloric input.
Because of the nature of the obesity problem, any product to reduce
the individual's appetite must be of such a character that
administration can safely and comfortably extend over a prolonged
period. Products such as amphetamine and 2-amino-1-phenylpropane,
have been used for this purpose, but when administered in
sufficient quantities to induce anorexia, the patient may
experience a number of undesirable side effects. For example, the
stimulating effect may be that an appetite depressant dose taken
shortly before the evening meal may make it difficult for the
patient to sleep without sedation. Work on this problem has,
therefore, been directed toward isolation and separation of
anorexia effects from those which produce an anti-depressant or
hypertensive activity.
It also has been noted recently that a number of the compounds
which are active as appetite depressants cause monoamine oxidase
inhibition and produce the side effects and toxic reactions
associated with such inhibition. These include such effects as
constipation, difficulty in micturition, blurred vision, dryness of
mouth and impotence. Ordinarily these effects are noted only with a
marked overdose, but their appearance at normal therapeutic doses
in sensitive individuals is a distinct probability. Other side
effects such as fluid retention, skin alterations, sweating, nausea
and headache have been reported.
Some patients receiving compounds causing monoamine oxidase
inhibition experienced hypertension and severe headaches after
ingesting quantities of aged cheese and other foods containing
tyramine such as certain beers, wines and yogurt.
It is highly desirable, therefore, that a compound to be used as an
appetite depressant produce a minimum hypertensive and stimulant
response. It is also desirable that an appetite depressant not
cause monoamine oxidase inhibition.
It is an object of this invention, therefore, to provide a compound
which is a good appetite depressant while exhibiting a minimum of
side effects.
It is a further object of this invention to provide a compound
which is an appetite depressant and causes very little stimulant
type side effects.
It is a still further object of this invention to provide a
compound which is an appetite depressant and relatively free from
monoamine osidase inhibitory activity.
These and other objects are achieved in general through the
provision of a substituted phenethylamine having the structural
formula wherein R and R.sub.1 are each hydrogen, halogen,
trifluoromethyl, diloweralkylamino, loweralkoxy and loweralkyl;
R.sub.2 is hydrogen, phenyl and loweralkyl; R.sub.3 is hydrogen,
straight and branched loweralkyl, aryl and trifluoromethyl; R.sub.4
is hydrogen, loweralkyl, loweralkanoyl and lowercarbalkoxy; and X
is cycloalkyl, cycloalkyl-loweralkyl, and its non-toxic acid
addition salts.
In addition to the above definitions, this invention contemplates
compounds, wherein R and R.sub.1, when at the 2- and 3-positions
respectively, together form a phenyl ring, which have the
structural formula and compounds wherein R and R.sub.1 when at the
3- and 4-positions respectively, together form a methylene dioxy
ring system of the formula
Generally, these compounds are prepared by reacting an amine
derivative of the formula NH.sub.2 --X wherein X is as previously
described, with an apporpriately substituted phenylacetone of the
structural formula wherein R, R.sub.1, R.sub.2 and R.sub.3 are each
as previously described. This reaction is carried out in an inert
solvent, by which is meant a solvent system which neither reacts
with the reactants or products, nor otherwise interferes with the
reaction, and yields a com-pound of the formula This compound is
then reduced by an appropriate reducing agent such as sodium
borohydride or lithium aluminum hydride, or by catalytic reduction,
or by other known reducing agents, to yield the product of Formula
I wherein R.sub.4 is hydrogen. Other radicals may be substituted
for hydrogen in the position indicated by R.sub.4 by acylation or
by acylation followed by reduction. An ester or alkanoyl halide may
be used for the acylation.
The compounds of this invention exhibited activity as anoretic
agents when administered orally or subcutaneously to rats in an
amount equal to from about 0.001 and about 0.1 millimoles per
kilogram of body weight. The compounds may be administered orally,
for example, as the base or as the hydrochloride salt in a saline
solution or in a capsule; administration may also be as a powder in
a capsule or in tablet form, these preparations being made
according to the usual procedures.
In order to better illustrate this invention, the following
examples are presented to demonstrate a few specific embodiments of
this invention and are not intended to limit same thereby.
EXAMPLE 1
p-Chloro-N-(cyclopropylmethyl)-.alpha.-methyl-phenethylamine
To 600 ml. of benzene is added 50.0 grams of p-chlorophenyl-acetone
and 22.8 grams of cyclopropylmethylamine. The mixture is heated to
reflux employing a Dean-Stark water separator and refluxed until no
more water separates. The reaction mixture is then concentrated and
the crude ketimine isolated. The crude ketimine is dissolved in 600
ml. methanol and the solution is cooled in an ice bath. To this
cooled solution is added 22.4 grams of sodium borohydride
portionwise with stirring, and the reaction mixture is refluxed for
4 hours. The solution is concentrated and 400 ml. of water is
added.
The mixture is rendered alkaline with 60 ml. of 45 percent aqueous
potassium hydroxide and 60 grams potassium hydroxide pellets and
the resulting oily mixture is extracted three times with ether. The
combined ether solutions are washed once with water and dried over
anhydrous magnesium sulfate. The solution is then filtered,
concentrated and distilled yielding 47.3 grams of
p-chloro-N-(cyclopropylmethyl)-.alpha.- methyl-phenethylamine
having a boiling point of 107.5.degree.-109.degree. C, at 1.3 mm,
n.sub.D.sup.25 1.5233.
The acid-addition salts of these compounds are prepared by
dissolving the base obtained in accordance with the procedure
outlined above, in anhydrous ether and adding the acid
corresponding to the salt desired. For example, the hydrochloride
salt of the compound prepared according to Example 1 is prepared by
dissolving the 47.3 grams of
p-chloro-N-(cyclopropylmethyl)-.alpha.-methyl-phenethylamine in 700
ml. of anhydrous ether and the mixture is cooled in an ice bath. To
this solution is added ethereal hydrochloric acid dropwise with
stirring precipitating the hydrochloride salt out of solution. The
acid is added until no more precipitate forms. In like manner,
other acid-addition salts may be prepared such as the phosphate,
sulfate, fumerate and oxalate, among others.
The procedure of Example 1 may be followed to prepare other
phenethylamine derivatives by reacting the appropriately
substituted phenylacetone with the desired amine derivative and
reducing the product of this reaction to yield the desired
compound. Following below in Table 1 is a list of compounds
prepared in accordance with this invention showing the respective
definitions of R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and X, with
reference to Formula I, and the identifying physical constants.
##SPC2## ##SPC3## ##SPC4## ##SPC5##
The compounds of Examples 37 through 40 are prepared according to
the method of Example 1 by substituting the correspondingly
substituted phenylacetone as the starting material. For example, to
prepare the compound of Example 37, the para-chlorophenylacetone is
replaced with 3,4-methylene dioxy phenylacetone and the starting
material for the compound of Example 38 is 1-naphthylacetone.
EXAMPLE 41
p-Chloro-N-(cyclobutylmethyl)-.alpha.-methyl-phenethylamine
A solution of 25.0 grams (0.188 mole)cyclobutylcarbonyl chloride in
200 ml. anhydrous ether is added dropwise with stirring to a cold
solution of 32.0 grams (0.188 mole) of
p-chloro-.alpha.-methylphenethylamine and 19.0 grams (0.188 mole)
tri-ethylamine in 200 ml. anhydrous ether. The mixture is allowed
to reach room temperature and stirred for 1 hour. The reaction
mixture is then filtered and the resulting solid washed with water.
The crude amide is then recrystallized from a methanol-water
solution yielding 37.9 grams of
N-(p-chloro-.alpha.-methyl-phenethyl)- cyclobutanecarboxamide.
A solution of 33.1 grams (0.131 mole) of the amide in 600 ml.
anhydrous ether is added dropwise with stirring to a suspension of
9.92 grams (0.262 mole) lithium aluminum hydride in 500 ml.
anhydrous ether and the mixture is refluxed for 20 hours. The
excess lithium aluminum hydride and the product complex are
decomposed by the successive addition of 9.9 ml. water 9.9 ml. 15
percent sodium hydroxide and 29.7 ml. water. The salts are then
filtered, washed well with ether and the filtrate is dried over
magnesium sulfate and concentrated. The crude product is distilled
at 1 mm. pressure of mercury, the fraction boiling at
124.degree.--126.degree. C, n.sub.D.sup.25 1.5222 collected as
p-chloro-N-(cyclobutylmethyl)- .alpha.-methyl-phenethylamine at a
yield of 80.2 percent or 25.0 grams. Elemental analysis for
C.sub.14 H.sub.20 CIN: Calculated: C=70.72%; H=8.48%; N=5.89%
Found: C=70.66%; H=8.64%; N=5.77% The hydrochloride salt of the
phenethylamine prepared according to Example 41 is prepared by
treating a solution of the phenethylamine in anhydrous ether with
ethereal hydrochloric acid. The hydrochloride salt is
recrystallized from a methanol-ether solution.
EXAMPLE 42
p-Chloro-N-(cyclopentylmethyl)-.alpha.-methyl-phenethylamine
Following the procedure of Example 41, the p-chloro-N-
(cyclopentylmethyl)-.alpha.-methyl-phenethylamine is prepared by
sub-stituting cyclopentylcarbonyl chloride for the
cyclobutylcarbonyl chloride. The resulting amide is then reduced to
the amine as described in the foregoing procedure. The resulting
p-chloro-N-(cyclopentylmethyl)- .alpha.-methyl-phenethylamine has a
boiling point of 132-134.degree.C at a mercury pressure of 1 mm.,
N.sub.D.sup.25 1.5228. elemental analysis for C.sub.15 H.sub.22
CIN: Calculated: C=71.55%; H=8.81%; N=5.56% Found: C=73.11%;
H=9.06%; N=6.02% The hydrochloride salt of the N-cyclopentylmethyl
phenethylamine derivative of Example 42 is prepared in the same
manner as described for the N-cyclobutylmethyl phenethylamine
derivative.
The following example illustrates the acylation step employing an
ester to replace the hydrogen at R.sub.4 of Formula I with a formyl
group.
EXAMPLE 43
p-Chloro-N-(Cyclopropylmethyl)-N-Formyl-.alpha.-Methyl-phenethylamine
A mixture of 22.3 grams (0.1 mole) of
p-chloro-N-(cyclo-propylmethyl)- .alpha.-methyl-phenethylamine
prepared according to Example 1 and 11 grams (0.15 moles) of
ethylformate were refluxed for 24 hours. The excess of formate was
removed and the residue was distilled at reduced pressure to give
12.5 grams of oil boiling at 117.degree.-119.degree. C at 1.4 mm.,
N.sub.D.sup.25, 1.5385. elemental analysis for C.sub.14 H.sub.18
ClNO: Calculated: C=66.79%; H=7.21%; N=5.56%; Cl= 14.08% Found:
C=66.86%; H=7.39%; N=5.61%; Cl- 14.07% The introduction of other
substituents in the R.sub.4 position is illustrated by the
following examples.
EXAMPLE 44
Preparation of
p-Chloro-N-(Cyclopropylmethyl)-.alpha.-Methyl-phenethyl
Carbamic Acid Ethyl Ester
A solution of 21.6 grams (0.20 moles) of ethyl chloroformate in 200
ml. of ether was added dropwise with stirring in a period of about
15 minutes into a solution of 44.8 grams (0.2 mol) of
p-chloro-N-(cyclopropylmethyl)- .alpha.-methyl-phenethylamine
prepared according to Example 1 and 20.2 grams (0.2 mole) of
triethylamine in 200 ml. of dry ether. A white precipitate formed
immediately. The mixture was stirred for one hour at room
temperature and filtered. The solid was dissolved in water and the
aqueous solution extracted with ether. The ethereal solutions were
combined, washed with water and dried over magnesium sulfate.
Isolation of the product by filtration and concentration of the
ethereal solution gave 44.6 grams of an oil as the crude ester.
This was distilled to give 38.9 grams of
p-chloro-N-(cyclopropyl-methyl)-.alpha.-methyl-phenethyl carbamic
acid ethyl ester with a boil-ing point of 154.degree.- 157.degree.C
at 1 mm., N.sub.D.sup.25, 1.5140. elemental analysis for C.sub.16
H.sub.22 ClNO: Calculated: C=64.97%; H=7.49%; N=4.73% Found:
C=64.84%; H=7.49%; N=4.74%
EXAMPLE 45
Preparation of p-Chloro-N-(Cyclopropylmethyl)-N-Methyl-.alpha.-
Methyl-phenylamine
A solution of 33.35 grams (0.113 mole) of the carbamic acid ethyl
ester of Example 44 in 200 ml. of dry ether was added dropwise with
stirring to a suspension of 8.56 grams (0.226 mole) of lithium
aluminum hydride in 1 liter of dry ether at a rate sufficient to
maintain gentle reflux. When the addition was complete, the
reaction mixture was refluxed and stirred for 2 hours. The complex
was then cautiously decomposed by the successive addition of 8.56
ml. of water, 8.56 ml. of 15% NaOH and 28.78 ml. of water. The
reaction mixture was filtered and dried over magnesium sulfate. The
ether, after filtration from the drying agent, was evaporated and
the residue was distilled to yield 22.5 grams of
p-chloro-N-(cyclopropylmethyl)-N-methyl-.alpha.-methyl-phenylamine
boiling at 114.degree.--116.degree. C at 1 mm. pressure,
N.sub.D.sup.25, 1.5226. elemental analysis for C.sub.14 H.sub.20
ClN: Calculated: C=70.72%; H=8.48%; N=5.89% Found: C=70.81%;
H=8.43%; N=5.80% The hydrochloride salt of the foregoing compound
was prepared from the base with gaseous HCl in ether.
The compounds of this invention exhibit good biological activity,
specifically as anoretic agents. It has been found that a dose
comprising a minor proportion of the compounds of this invention in
a major proportion of carrier when administered orally or
subcutaneously to rats produces a marked reduction of food intake
of the test rats over the controls. Water soluble compounds are
usually administered subcutaneously in a saline solution containing
0.01 to 0.05 millimoles per ml.; water insoluble compounds are
suspended in gum tragacanth (0.3 percent gum in water) and the
effective dose administered orally in water suspension at the rate
of 2 ml./kg.
The test procedure utilized to illustrate this biological activity
is a relatively simple test. Two groups of four rats each are
placed on a 5-hour feeding schedule, that is, the total feeding
period for a 24 hour period is 5 hours for each group at the same
time of the day, 7 days a week. Approximately one-half hour before
the feeding time is to commence, the control group is administered
saline solution and the test group is administered a dosage of the
test compound. In this experiment, two different dosage levels of
0.011 and 0.044 mM./kg. of body weight were administered to
different test groups. A measured amount of feed is given to both
groups (the same amount for each group) and at the end of the 5
hour feeding period, the food remaining is measured to determine
intake. The test animals are compared to the controls in accordance
with the following scoring system: % Food Intake Less Rating than
Controls 0 5 or less .+-. 6-19 1+ 20-39 2+ 40-59 3+ 60-89 4+ 90
& over
Following below is Table II showing the activity of a few species
of the compounds of the instant invention based upon the
above-mentioned scoring system. Except where noted, the rating is
at a dose of 0.011 mM./kg. and at 0.044 mM./kg.
The side effects of the compounds also were observed and notes made
of responses such as increased irritability, ataxia, salivation,
convulsions, tail-lash and the like. These are noted as mild,
moderate and severe; a rating of mild, however, also includes zero
side effects and does not necessarily indicate the presence of some
side effects.
Monoamine oxidase inhibition was also noted at dosage levels of 5,
10, 25, 50 and 100 mg./kg. of body weight. That those compounds of
Formula I wherein X has four or more carbon atoms cause
surprisingly little monoamine oxidase inhibition is apparent from
the results shown in Table II.
TABLE II
Appetite Depressant Activity of Substituted Phenethylamines
Compound Rating 0.011 0.044 Side MAOI* mM/kg mM/kg Effects
_________________________________________________________________________
_ 1. p-chloro-N- cyclobutyl- .alpha.-methyl- 3+ 4+ mild phenethyl-
amine 2. p-chloro-N- cyclopentyl- .alpha.-methyl- 1+ 3+ mild Neg.
phenethyl- at 50 amine.sup.. HCl 3. p-chloro-N- cyclopropyl-
methyl-.alpha.- 3+ 4+ mild Neg. methyl-phen- at 50 ethylamine.sup..
HCl 4. p-fluoro-N- cyclopropyl- methyl-.alpha.- 2+ 2+ methyl-phen-
ethylamine 5. N-cyclopropyl- .alpha.-propyl-phen- .+-. 3+
ethylamine 6. p-chloro-N- cyclopropyl- 3+ 4+ .alpha.-methyl-
phenethylamine 7. p-dimethylamino- N-cyclopropyl-.alpha.- 2+ 3+
moderate Neg. methyl-phen- to at 50 ethylamine severe 8.
p-chloro-N- (3-hydroxy- propyl)-.alpha.- 1+ 2+ methyl-phen-
ethylamine.sup.. HCl 9. p-dimethyl- amino-N- cyclobutyl- 3+ 3+ mild
Neg. .alpha.-methyl- at 25 phenethyl- amine 10. m-trifluoro-
methyl-N- cyclopropyl- methyl-.alpha.- 3+ 3+ mild Neg. methyl-phen-
at 50 ethylamine.sup.. HCl 11. m-trifluoro- methyl-N- cyclopropyl-
1+ 3+ moderate .alpha.-methyl- to phenethyl- severe amine.sup.. HCl
12. m-trifluoro- methyl-N- cyclobutyl- 3+ (1) mild Neg.
.alpha.-methyl- at 100 phenethyl- amine 13. N-cyclopropyl-
methyl-p- (dimethylamino)- 3+ (2) mild Neg. .alpha.-methyl- at 50
phenethylamine 14. N-cyclopropyl- .alpha.-methyl-p- (trifluoro- 3+
(2) mild Neg. methyl)phen- at 10 ethylamine 15. p-chloro-N-
(cyclopropyl- methyl)-N- 2+ 3+ mild Neg. methyl-.alpha.-
methyl-phen- ethylamine
FOOTNOTE: * Monoamine oxidase inhibition - dose indicated in
mg./kg.
FOOTNOTE: (1) at 26 mg./kg. administered
orally---------------------------
------------------------------------------------(2) at 12-13
mg./kg. administered subcutaneously
The compounds of this invention may be administered as bases, or
more conveniently as acid-addition salts. The route of
administration may be oral, intraperitoneal, subcutaneous, and
intravenous, among others. As can be observed from the Table above,
these compounds exhibit marked activity as appetite depressants
without undesirable side effects.
* * * * *